Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients with Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial

Arthritis Care and Research

Volumn 68, Issue 6, 2016, Pages 744-752

  Emery, Paul ^a   Fleischmann, Roy M ^b   Strusberg, Ingrid ^c   Durez, Patrick ^d   Nash, Peter ^e   Amante, Eric Jason B ^f   Churchill, Melvin ^g   Park, Won ^h   Pons Estel, Bernardo ⁱ   Han, Chenglong ^j   Gathany, Timothy A ^j   Xu, Stephen ^k   Zhou, Yiying ^k   Leu, Jocelyn H ^k   Hsia, Elizabeth C ^l  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Instituto Reumatológico Strusberg   (Argentina)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f PHILIPPINE GENERAL HOSPITAL   (Philippines)

^g Arthritis Center of Nebraska   (United States)

^h Inha University Hospital   (South Korea)

ⁱ Sanatorio Parque   (Argentina)

^j Janssen Global Services LLC   (United States)

^k JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBODY; C REACTIVE PROTEIN; GOLIMUMAB; METHOTREXATE; NEUTRALIZING ANTIBODY; PLACEBO; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMERICAN COLLEGE OF RHEUMATOLOGY CRITERIA; APPENDICITIS; ARTICLE; ASPERGILLOSIS; BASAL CELL CARCINOMA; BREAST CANCER; BRONCHITIS; CLINICAL DISEASE ACTIVITY INDEX; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; COUGHING; DAS28; DEMYELINATION; DISEASE ACTIVITY; DISEASE ASSESSMENT; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; GASTROINTESTINAL DISEASE; HEALTH ASSESSMENT QUESTIONNAIRE; HERPES ZOSTER; HODGKIN DISEASE; HUMAN; IMMUNOGENICITY; INFESTATION; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INTENTION TO TREAT ANALYSIS; INTESTINE TUBERCULOSIS; LUNG TUBERCULOSIS; LYMPHOMA; MAJOR CLINICAL STUDY; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NAUSEA; NON MELANOMA SKIN CANCER; NON SMALL CELL LUNG CANCER; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PNEUMONIA LEGIONELLA; PROTEIN BLOOD LEVEL; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SEPSIS; SHARP/VAN DER HEIJDE SCORE; SHORT FORM 36; SIMPLIFIED DISEASE ACTIVITY INDEX; TUBERCULOUS PLEURISY; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERUS MYOMA; AGED; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84970005265     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22759     Document Type: Article

References (24)

1. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al., Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009; 60: 2272-83.
2. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al., Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009; 68: 789-96.
3. Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al., Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009; 374: 210-21.
4. Emery P, Fleischmann RM, Doyle MK, Strusberg I, Durez P, Nash P, et al., Golimumab, a human anti-tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Care Res (Hoboken) 2013; 65: 1732-42.
5. Emery P, Fleischmann R, van der Heijde D, Keystone EC, Genovese MC, Conaghan PG, et al., The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 2011; 63: 1200-10.
6. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al., American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
7. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL., Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the Preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 34-40.
8. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al., A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42: 244-57.
9. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al., Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796-806.
10. Fries JF, Spitz P, Kraines RG, Holman HR., Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
11. Lubeck DP., Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. Pharmacoeconomics 2004; 22: 27-38.
12. Ware JE Jr, Sherbourne CD., The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
13. Van der Heijde DM, van Leeuwen MA, van Riel PL, Koster AM, van 't Hof MA, van Rijswijk MH, et al., Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992; 35: 26-34.
14. Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, et al., Pharmacokinetics and safety of golimumab, a fully human anti-TNF-α monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 2007; 47: 383-96.
15. Van Riel PL, van Gestel AM, Scott DL., EULAR handbook of clinical assessments in rheumatoid arthritis. Alphen Aan Den Rijn (The Netherlands): Van Zuiden Communications; 2000.
16. Aletaha D, Smolen JS., The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 2007; 21: 663-75.
17. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al., American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63: 573-86.
18. Genovese MC, Bathon JM, Fleischmann RM, Moreland LW, Martin RW, Whitmore JB, et al., Long-term safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol 2005; 32: 1232-42.
19. Van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewe R, Patra K, et al., Disease activity, physical function, and radiographic progression after long-term therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol 2010; 37: 2237-46.
20. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al., Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28: 1238-44.
21. Burmester GR, Matucci-Cerinic M, Mariette X, Navarro-Blasco F, Kary S, Unnebrink K, et al., Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study. Arthritis Res Ther 2014; 16: R24.
22. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al., Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011; 50: 124-31.
23. Hsia EC, Cush JJ, Matteson EL, Beutler A, Doyle MK, Hsu B, et al., Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in phase III clinical trials. Arthritis Care Res (Hoboken) 2013; 65: 309-13.
24. Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, et al., Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor α therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009; 60: 3180-9.